Trial result ·
Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This early trial tested ABBV-368, an antibody that switches on OX40, in advanced solid tumors. It was the first test in humans. Some people got it alone. Others got it with the drug budigalimab. The drug alone was given in triple-negative breast cancer. The pair was given in head and neck cancer. 139 people were treated. The main goals were safety, tolerability and how the drug moves in the body.
What they found
ABBV-368 showed dose-proportional drug levels. Budigalimab did not change this. Treatment-related side effects occurred in each group. Some patients had serious colitis linked to the treatment. There were complete and partial confirmed responses. Markers showed CD8 T-cell activation. They also showed activity driven by interferon-gamma.
What it means for patients
The authors say ABBV-368, with or without budigalimab, was well tolerated. They say it caused dose-specific immune cell activation. They say more combination or optimization strategies are needed for meaningful clinical benefit.
Why it is not certain yet
This was an early phase 1 trial. It mainly aimed to check safety. Efficacy was only an early look. The abstract says further strategies are needed for clinical benefit. It gives only a few confirmed responses.
Source
Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors.
PubMed · PMID 42956185We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Triple-negative breast cancer publications